News

| Sagit Amit Evan
December 31st, 2017

Gornitzky represents Priority Software in its acquisition of Acclivity LLC.

Gornitzky represented Priority Software in its acquisition of Acclivity LLC, a U.S. based ERP software developer for small and mid-size companies worldwide, and its affiliated LLCs.

Priority is a portfolio company of Fortissimo Capital, a prominent Israeli private equity fund and this is its fourth acquisition in recent months represented by our firm.

Priority was represented by Chaim Friedland (Partner), Sagit Amit Evan (Senior Associate), Nir Knoll (Associate).

July 30th, 2017

Gornitzky represents Priority in its acquisition of Monitin Information Systems' ERP operations.

Gornitzky represented Priority Software in its acquisition of the entire ERP operations of Monitin Information Systems, a long-standing ERP developer and implementor for numerous Israeli corporations.

 

Priority is a portfolio company of Fortissimo Capital, a prominent Israeli private equity fund and this is its third acquisition in recent months represented by our firm.

 

We congratulate Priority on its continued expansion in Israel and abroad.

 

Priority was represented by Sagit Amit Evan (Senior Associate), Eitan Mor (Associate), Daniel Reshef (Associate) and Ori Sheinkman (Associate).

May 11th, 2017

Gornitzky represented the underwriters, led by Jefferies and Cowen & Company, in the USD 67 million IPO of UroGen Pharma Ltd. on the NASDAQ Global Market.

Gornitzky represented the underwriters, led by Jefferies and Cowen & Company, in the USD 67 million IPO of UroGen Pharma Ltd. on the NASDAQ Global Market. UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology.

 

The IPO was the first major underwritten IPO of an Israeli company in the United States since 2015.

 

Jefferies and Cowen & Company acted as joint book-running managers for the offering. Raymond James & Associates and Oppenheimer & Co. acted as co-managers for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan (Associate).

 

July 22nd, 2015

Gornitzky represents the underwriters, led by Nomura and Roth Capital, in RedHill Biopharma’s USD 40 million public offering of ADSs

 

 

 

 

 

Gornitzky represented the underwriters, led by Nomura and Roth Capital Partners, in RedHill Biopharma’s USD 40 million public offering of American Depository Shares (ADSs) on the NASDAQ Capital Market. RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on drugs for inflammatory and gastrointestinal diseases, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).

 

Nomura Securities and Roth Capital Partners acted as joint book-running managers for the offering. MLV & Co. and H.C. Wainwright acted as co-managers for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan.

 

 

March 4th, 2014

Gornitzky & Co. represented the underwriters, led by Goldman Sachs, Credit Suisse and Jefferies, in Lumenis Ltd.’s USD 75 million public offering on the NASDAQ Global Select Market.

Gornitzky & Co. represented the underwriters, led by Goldman Sachs, Credit Suisse and Jefferies, in Lumenis Ltd.’s USD 75 million public offering on the NASDAQ Global Select Market.

 

Goldman Sachs, Credit Suisse and Jefferies acted as joint book-running managers for the offering. Wells Fargo Securities acted as co-manager for the offering.


The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan.

October 1st, 2017

Gornitzky represents the underwriters, led by Cowen and Company and Wells Fargo, in MediWound’s follow-on offering on NASDAQ.

Gornitzky represented the underwriters, led by Cowen and Company and Wells Fargo Securities, in the USD 25 million follow-on offering of MediWound Ltd. on the NASDAQ Global Market. MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications.

 

Cowen and Company, LLC and Wells Fargo Securities, LLC acted as joint book-running managers for the offering. Oppenheimer & Co. Inc. and SunTrust Robinson Humphrey, Inc. acted as co-lead managers for the offering. Aegis Capital Corp. acted as a co-manager for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner), Sagit Amit Evan (Senior Associate), together with Associates Danielle Skald and Daniella Segal.

June 1st, 2017

Gornitzky represents Telrad Networks Ltd. in an IPO on TASE.

Gornitzky represented Telrad Networks Ltd., a global provider of innovative telecom solutions, including wireless communication products, in a NIS 162 million IPO on TASE; the IPO was carried out through a combination of the issuance of shares by the Company, along with an offer for sale of shares by the Company's shareholders.

 

Telrad Networks was represented by Yair Shiloni (Partner), Sagit Amit Evan (Senior Associate) and Itamar Ben-Yehuda and Netalee Aviv (Associates).

December 2nd, 2015

Gornitzky represents the underwriters, led by Apex Issuances, in a NIS 265 million unsecured bonds IPO on the Tel Aviv Stock Exchange, made by Strawberry Fields REIT, Ltd.

Gornitzky represents the underwriters, led by Apex Issuances, in a NIS 265 million unsecured bonds IPO on the Tel Aviv Stock Exchange, made by Strawberry Fields REIT, Ltd, a BVI company based in the U.S. which owns 39 income generating properties in the U.S., used as retirement homes and medical facilities. 

 

The underwriters were represented by Yair Shiloni (partner) and Sagit Amit Evan.

February 15th, 2015

Gornitzky & Co. represented the underwriters, led by Wells Fargo, in RedHill Biopharma’s USD 14.4 million public offering of American Depository Shares (ADSs) on the NASDAQ Capital Market.

Gornitzky & Co. represented the underwriters, led by Wells Fargo, in RedHill Biopharma’s USD 14.4 million public offering of American Depository Shares (ADSs) on the NASDAQ Capital Market. RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on drugs for inflammatory and gastrointestinal diseases, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).

 

Wells Fargo Securities acted as lead book-running manager and Roth Capital Partners acted as joint book-running manager for the offering. MLV & Co acted as co-manager for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan.


For more information on our capital markets practice, please click here.